Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
October 23, 2024 07:00 ET
|
GENENTA SCIENCE SPA
Genenta’s CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
October 02, 2024 06:30 ET
|
GENENTA SCIENCE SPA
Genenta Secures Approval for Innovative Trial for
Metastatic Renal Cell Cancer
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
May 06, 2024 06:25 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
February 08, 2024 05:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of...
Genenta to Present at Upcoming Scientific and Investor Conferences
September 06, 2023 07:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
July 28, 2023 03:00 ET
|
GENENTA SCIENCE SPA
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science...
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
June 29, 2023 07:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...
Genenta to Provide Update on Lead Product Temferon™
May 16, 2023 07:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage...
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
April 26, 2023 07:00 ET
|
GENENTA SCIENCE SPA
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN,...